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Background and Purpose: Over the last years an increasing incidence of Clostridium difficile-associated diarrhea
(CDAD) has been reported. Especially haematology-oncology patients are at risk of developing CDAD.
The aim of this analysis is to determine the incidence of CDAD in radiooncological patients and to find out what
relevance CDAD has for the feasibility of the radiooncological treatment, as well as to detect and describe risk factors.
Patients and Methods: In a retrospective analysis from 2006 to 2010 34 hospitalized radiooncological patients
could be identified having CDAD. The risk factors of these patients were registered, the incidence was calculated
and the influence on the feasibility of the radiooncological therapy was evaluated. Induced arrangements for
prophylaxis of CDAD were identified and have been correlated with the incidence.
Results: The incidence of CDAD in our collective is 1,6%. Most of the patients suffering from a CDAD were treated
for carcinoma in the head and neck area. Common risk factors were antibiotics, proton pump inhibitors, cytostatic
agents and tube feeding.
Beside a high rate of electrolyte imbalance and hypoproteinemia a decrease of general condition was frequent. 12/
34 patients had a prolonged hospitalization, in 14/34 patients radiotherapy had to be interrupted due to CDAD. In
21 of 34 patients a concomitant chemotherapy was planned. 4/21 patients could receive all of the planned cycles
and only 2/21 patients could receive all of the planned cycles in time.
4/34 patients died due to CDAD. In 4/34 patients an initially curative treatment concept has to be changed to a
palliative concept.
With intensified arrangements for prophylaxis the incidence of CDAD decreased from 4,0% in 2007 to 0,4% in 2010.
Conclusion: The effect of CDAD on the feasibility of the radiotherapy and a concomitant chemotherapy is
remarkable. The morbidity of patients is severe with a high lethality.
Reducing of risk factors, an intense screening and the use of probiotics as prophylaxis can reduce the incidence of
CDAD.
Keywords: Clostridium difficile-associated diarrhea, Clostridium difficile, Diarrhea, Colitis, Radiotherapy, Radiation
Therapy, Chemoradiation
Background and Purpose
Clostridium difficile (CD) appears normally as a harm-
less environmental gram positive anaerobic bacteria
which becomes pathogen in several circumstances [1,2].
Clostridium difficile can be isolated from the stool of up
to five per cent of healthy adults. Some strains produce
toxin and can therefore cause diarrhea [3]. CD is the
aetiological agent for most of the cases of pseudo mem-
branous colitis. Over the last years an increasing inci-
dence of Clostridium difficile-associated diarrhea
(CDAD) has been reported. Furthermore, more severe
courses of the disease have been described because of
new virulent strains [3-6].
Several risk factors for CDAD are known. Beside anti-
biotic intake, other drugs like immunosuppressant,
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cytostatic agents and proton pump inhibitors (PPI) have
been identified to trigger CDAD [5,7-10]. Also tube
feeding, parenteral nutrition as well as a reduced general
condition and compromised immune function have
been described as risk factors [1,2,11].
Especially haematology-oncology patients are at risk of
developing CDAD [12-15]. Those haematology-oncology
patients often have systemic diseases and in many cases
receive high dosed chemotherapy.
Radiooncological patients are mostly suffering from
localised tumour and receive radiotherapy alone or with
a moderate dosed concomitant chemotherapy compared
to chemotherapy of haematology patients. Because of
the mainly local therapy radiooncological patients have
higher local toxicity. Especially stomatitis, mucositis and
dysphagia are common in radiooncological patients and
might be relevant as risk factors.
In summary a lot of radiooncological patients have
several risk factors. Beside concomitant chemotherapy,
the frequency of a treatment with PPI and antibiotics is
estimated to be high on a radiooncological ward
[16-19]. Also tube feeding and parenteral nutrition is
common [20-22].
CDAD has a lethality of 0.5% to 2.0% and an increas-
ing morbidity [3,14]. A high morbidity and a negative
influence on the treatment of the underlying disease
have been documented, especially for surgical patients
or patients on intensive care units [23,24]. A high num-
ber of acute renal failure, weight loss, electrolyte imbal-
ance and hypoproteinemia have been described [5,23].
The influence of CDAD for the treatment of oncologi-
cal patients is not well reviewed. Because of the existing
data, multiple problems for the treatment of those
patients can be assumed [25,26].
Often inpatient stay is prolonged because of CDAD.
The costs for the health care system are high. There are
data showing estimated additional costs between 5243
US$ and 8570 US$ in Europe per patient with a primary
episode of CDAD and over 13600 US$ for a case of
recurrent CDAD [5,27].
Referring to this data, there might be a negative influ-
ence on the feasibility of a radiooncological treatment
for patients suffering from a CDAD.
The aim of this analysis is to determine the incidence
of CDAD in radiooncological patients and to find out
what relevance CDAD has for the feasibility of the
radiooncological treatment, as well as to detect and
describe risk factors.
Patients and Methods
The study was performed for patients of a department
of radiotherapy of a German university hospital. In- and
outpatients were looked up for CDAD. Only inpatients
could be identified developing CDAD during radioonco-
logical treatment.
In a retrospective analysis from 2006 to 2010 34 hos-
pitalized radiooncological patients could be identified
having CDAD. In that time 2150 patients were on the
radiooncological ward in total (484 in 2006, 398 in
2007, 423 in 2008, 384 in 2009 and 461 in 2010).
Radiooncological inpatients were identified from CD
positive patients registered in the department for micro-
biology and hygiene. Beside that, the enquiry was done
by checking codification for final payment. All patients
had to have at least one stool sample being tested posi-
tive for CD toxin A or B.
Until the year 2008 all inpatients with watery diarrhea
of more than 24 hours and all patients with medical his-
tory of antibiotic intake and non-watery diarrhea of
more than 48 hours were screened for CDAD. Beside
that all patients with any diarrhea of more than 72
hours were screened for CDAD. For all patients a stool
sample was collected and screened for Clostridium diffi-
cile toxin A and B by enzyme immunoassay.
Since 2008 for all patients with any diarrhea longer
than 24 hours were screened for CD toxin A and B. In
case of clinical suspicion of CDAD and negative findings
for CD toxin A or B, two more stool samples were
screened by enzyme immunoassay.
Since 2009 for all patients a stool sample was cultured
for toxigenic CD additionally to the enzyme
immunoassay.
All patients with positive findings for CD toxin A or B
had clinical symptoms of CDAD. In our collective no
asymptomatic carrier could be identified.
In case of suspicion of a relapse of CDAD, beside
screening for CD toxin A and B, a sigmoidoscopy was
performed and a stool sample was cultured for toxigenic
CD.
The risk factors of the patients were registered. Anti-
biotics and cytostatic agents applicated up to four weeks
prior to diagnosis of CDAD were assessed. Patients with
a long time medication of immunosuppressive drugs or
patients with a Leukopenia CTC grade IV were counted
as immunosupressed. The influence on the feasibility of
the radiooncological therapy in terms of interruption or
abandonment of the radiotherapy, change of therapy
concept and the effect on the feasibility of chemother-
apy were evaluated.
Induced arrangements for prophylaxis of CDAD were
identified and have been correlated with the incidence.
Results
Patient’s characteristics
The incidence of CDAD in our collective is 1,6% (34 of
2150 patients). Of the 34 patients having a CDAD,
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24 were male, 10 were female. The median age was 67
Years with a standard deviation of 10 Years (Range from
46 to 85 years).
Most patients suffered from a head and neck cancer
or metastases in the head and neck area.
Treatment areas were in 21 cases the head and neck. 7
patients were treated thoracically, 5 pelvic and one
abdominal (Table 1).
The average treatment time was 41 days with a stan-
dard deviation of 19 days (Range from 5 to 74 days).
The average time as inpatients was 36 days with a stan-
dard deviation of 22 days (Range from 2 to 80 days).
Risk factors
The following data in terms of risk factors were col-
lected: The median pre treatment Karnofsky
Performance Status (KPS) of the patients was 70%
(range from 40% to 100%).
Twenty patients out of 34 (59%) had an antibiotic
treatment up to four weeks before developing diarrhea.
The most common antibiotic being taken was Pipera-
cillin/Combactam with 29% of all patients (10/34
patients) and 50% of the patients having an antibiotic
treatment (10/20). Beside Piperacillin/Combactam,
Ciprofloxacin (24% of all patients (8/34), 40% of the
patients receiving antibiotics (8/20)) and Moxifloxacin
(18% (6/34), 30% (6/20)) were frequently used. In 2006
and 2007 Moxifloxacin was frequently given. 45% (5/11)
of the patients with antibiotic treatment in that period
received Moxifloxacin. Since suspicions arose that Moxi-
floxacin triggers CDAD, in an antibiotic stewardship
Moxifloxacin wasn’t given in routine since 2008. Only
one more patient since 2007 developed a CD infection
after receiving Moxifloxacin.
Beside antibiotics, PPI, cytostatic agents and tube feed-
ing were common in radiooncological patients.
Of the 18 patients with nutrition via gastric tube, 14
had tube feeding as the only food intake. There was no
patient on parenteral nutrition as the only food intake
(Table 2).
Treatment of CDAD
For all patients with CDAD therapy with PPI, antibiotics
and cytostatic agents was paused or stopped if possible.
In two patients no further antibiotic treatment for CD
was necessary. Since 2007 all patients were treated with
probiotics (Saccharomyces boulardii) until there were no
more clinical symptoms for two days.
Following the guidelines and recommendations of the
Robert Koch Institute patients were treated with metro-
nidazole as the first line therapy to avoid vancomycin
resistant enterococci. According to the dysphagia of the
patients metronidazole was given oral, via gastric tube
or parenteral.
Patients with a severe diarrhea, with a KPS of less
than 60% or with more than two episodes of CDAD
were treated with oral vancomycin as first line therapy.
If the symptoms did not disappear within five days of
treatment with metronidazole the therapy was changed
to vancomycin. 4 Patients were treated with combina-
tion of parenteral metronidazole and enteral
vancomycin.
The average treatment time with antibiotics was 15
days (range from 5 to 83 days).
Arrangements for prophylaxis
Since 2008 the arrangements for prophylaxis have been
intensified. Antibiotics and PPI were restricted in use.
Tube feeding and parenteral nutrition as the only food
intake was avoided. All patients with diarrhea
Table 1 Patient characteristics
sex Underlying disease
1 F Anaplastic thyroid carcinoma
2 M Squamous cell carcinoma of the head and neck (SCCHN)
3 F Thyroid metastasis of an renal cell carcinoma
4 M SCCHN
5 F Cervical carcinoma
6 M SCCHN
7 M Bronchial carcinoma with a simultaneous SCCHN
8 F SCCHN
9 M Bronchial carcinoma
10 M SCCHN
11 M SCCHN
12 F SCCHN
13 M Bronchial carcinoma
14 M M. Hodgkin
15 M Bronchial carcinoma
16 M SCCHN
17 M Anal carcinoma
18 M Bronchial carcinoma
19 F Giant cell B-NHL with an abdominal bulk
20 M SCCHN
21 F Rectal carcinoma
22 M SCCHN
23 M SCCHN
24 M SCCHN
25 M Oesophageal carcinoma
26 M SCCHN
27 F SCCHN
28 M SCCHN
29 F Cervical carcinoma
30 M Pelvine bone metastasis of a rectal carcinoma
31 M Oesophageal carcinoma
32 F SCCHN
33 M SCCHN
34 M SCCHN
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continuing longer than 24 hours and clinical suspicion
of having CDAD were isolated prophylactically.
Isolation implicates a single room with a separate
bathroom. Gloves and special gowns were used by the
staff dealing with the patients on the ward and the staff
dealing with the patient at the linear accelerator. Addi-
tional hand hygiene with water and soap for all persons
exiting the isolation room was performed as well as for
the staff dealing with the patient at the linear accelera-
tor. Surface disinfection was intensified with sodium-
hypochloride.
In consultation with the Department of medical
Microbiology and Hygiene in an antibiotic stewardship
Moxifloxacin was not used in clinical routine since
2008.
Patients with four or more risk factors received pro-
biotic medication (Saccharomyces boulardii) during the
radiooncological treatment. Those patients with one epi-
sode of CDAD received probiotic medication for the
remaining radiooncological treatment.
The chronological incidence of CDAD showed one
patient of 484 in 2006 (incidence 0,2%), 16 of 398 in
2007 (4,0%), 11 of 423 in 2008 (2,6%), 4 of 384 in 2009
(1,0%) and 2 of 461 in 2010 (0,4%).
Complications of CDAD
The effect of CDAD on patient treatment showed 24 of
34 patients (73%) with an electrolyte imbalance. Of
those patients 15/24 (63%) had an imbalance on two or
more electrolytes. 4/34 patients needed intravenous
Table 2 Risk Factors
Age [years] KPS Antibiotic treatment PPI Cytostatic agents Tube feeding Parenteral nutrition Immuno-suppression
1 85 40% + + - + - -
2 51 60% - + + + - -
3 69 60% + + - - - -
4 71 60% + + - + - -
5 46 90% - - + - - -
6 53 70% - + + + + -
7 67 80% + + + - - -
8 70 70% - + + + - -
9 66 70% + + - - - -
10 63 60% + - + + + -
11 81 60% + - - - + -
12 82 70% + + + + - -
13 70 50% + + - - - -
14 46 80% - + + - + -
15 67 60% + + + - - +
16 60 80% - - + - - -
17 59 60% + + + - - -
18 64 60% + + + - - +
19 68 70% + + + - - +
20 52 70% - + + + - -
21 81 50% - + - - - -
22 56 80% - - + + - -
23 61 70% - + - + - -
24 71 90% - - + + - -
25 74 100% - - + - - -
26 64 50% - + - + - -
27 69 70% + + + + - +
28 70 70% + + - + - -
29 57 90% + + + - - -
30 60 50% + + + - - -
31 85 80% - + + + - -
32 73 60% + - - + - -
33 75 50% + + - + - +
34 63 70% + + + + - -
Hautmann et al. Radiation Oncology 2011, 6:89
http://www.ro-journal.com/content/6/1/89
Page 4 of 7
substitution of the electrolytes, the others an oral or
enteral substitution.
27/34 patients (79%) developed a hypoproteinemia
with a need to treat it in 12/27 (43%) of these patients.
Initially the median KPS of the patients was 70%.
After healing of the CDAD the median KPS was 50%.
12/34 patients (35%) had a prolonged hospitalization
of 7 days in average (range from two to 75 days). The
patient with prolonged inhabitation of 75 days had to be
treated on intensive care unit for most of the time.
12/34 patients had more than one episode of CDAD
during radiooncological treatment. All of these patients
had two episodes except one who had three.
In 14/34 patients (42%) radiotherapy had to be inter-
rupted because of CDAD. This interruption was four
days in average (range one to 27 days).
Of those 14 patients with interruption of radiation the
average interruption was 10 days. In two patients radio-
therapy could not be restarted.
In 21 of the 34 patients a concomitant chemoradiation
was planned. For those 21 patients 89 cycles were
planned altogether. 43% of the chemotherapy cycle (38
of 89 cycles) could be applicated.
In 62% of the cases (13/21 patients) chemotherapy had
to be stopped and could not be continued. Only 19% of
the patients (4/21 patients) could receive all of the
planned cycles and only 10% of the patients (2/21
patients) could receive all of the planned cycles in time.
In four patients an initially curative concept had to be
changed into a palliative treatment concept. A reduced
general condition after the CDAD did not allow treating
them in the initially planned concept.
Four patients (12%) died due to CDAD. One patient
died in a septicaemia. Three patients did not recover
adequate after the infection and died of complications.
Two of the patients were treated with the combination
of metronidazole and vancomycin. One patient was trea-
ted with vancomycin and for the last patient treatment
was started with enteral metronidazole. This patient
refused further therapy of CDAD because of the
advanced tumour stage and died of septicaemia.
Discussion
The incidence in our collective is with 1,6% high com-
pared to data in literature. Reichardt et al. describes an
incidence of 0,1% for Europe and an incidence of 0,1%
to 2% for the USA [3]. Heinlen et al. could found an
incidence of 0,6% for the USA in the year 2003 [28].
Especially the patients with head and neck cancer have
a high risk of developing CDAD. This might be due to a
multitude of risk factors. 19/34 of our patients were suf-
fering from a squamous cell carcinoma of the head and
neck (SCCHN).
Chemoradiation is a standard treatment for different
carcinomas [17,29-31]. Many patients on radiooncologi-
cal wards have at least this as a major risk factor
[16,17,32]. Some of these patients develop Neutropenia
and are therefore immunocompromised [18,19].
Several underlying diseases, mainly a reduced general
condition and compromised immune function have
been described as risk factors to develop CDAD [1,11].
Hospitalized radiooncological patients often need an
antibiotic or antimycotic medication during radiotherapy
[21,22]. Beside those risk factors, the frequency of a
treatment with proton pump inhibitor is estimated to be
quiet high on radiooncological wards. Tube feeding and
parenteral nutrition favour the onset of CDAD [3,33,34].
Especially head and neck cancer patients have a high
rate of dysphagia [18]. Nearly all patients having a dys-
phagia of CTC grade II or higher requiring tube feeding
or parenteral nutrition [20,35]. Wolff et al. found a rate
of dysphagia in head and neck tumour patients of 77%
and a rate of Grad 3 leukopenia or higher of 11% [18].
In our collective all head and neck cancer patients but 3
were addicted to tube feeding or parenteral nutrition
(18/21).
There are data identifying underlying diseases of the
gastrointestinal tract to be risk factors for CDAD [2,3].
Whether abdominal or pelvine radiotherapy triggers
CDAD is not known. In our collective only one patient
received abdominal and five patients received pelvic
radiotherapy.
Some data give evidence that haematological and
oncological patients are patients at risk for developing
CDAD [12-14]. Most data exist for paediatric oncologi-
cal units and for bone marrow transplant units
[12,15,36,37]. In the reports on haematology-oncology
patients, that include patients undergoing radiotherapy,
no subgroup analysis was done for that collective of
patients [13]. In summary there are no data about the
risk for radiooncological patients suffering from CDAD.
Our data confirm the assumption that radiooncologi-
cal patients are also patients at risk for an infection with
clostridium difficile.
Several authors have shown a decrease in local control
for different tumours due to unplanned interruptions of
radiotherapy [38,39]. Bese et al. reported a decrease of
1.4% per day of unplanned interruption for head and
neck carcinomas. SCCHN are common in our collective
and often have an interruption of radiotherapy.
42% of the patients developing a CDAD need a pause
of the radiation. For those patients who have an inter-
ruption of the radiotherapy, the average interruption
time is ten days. A decrease of loco regional control of
10 to 12% for one week of interruption has been
reported [38,40].
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Beside interruption of radiotherapy patients suffering
from CDAD have several additional factors decreasing
the feasibility of the oncological treatment like weight
loss, incomplete chemotherapy and a decrease of general
condition.
For bronchial carcinoma, studies have emphasized the
importance of prolonged overall treatment time. One
study suspected an increase of the risk of death of 2%
even for a one day break [41]. A statistically significant
decrease in overall survival for patients receiving a
radiochemotherapy for SCLC could be found [38].
Beside bronchial carcinoma and head and neck cancer,
also for cervical carcinoma, anal cancer and several
other carcinomas it has been reported that prolongation
of overall treatment time and interruption of radiother-
apy decreases the loco regional control [38]. For that
reason, a CDAD is a serious problem for patients under-
going radiotherapy.
Also the feasibility of chemotherapy concomitant to
radiotherapy is important for loco regional control and
overall survival [42]. Several authors suspect the cumu-
lative dose of concomitant chemotherapy to be an
important prognostic factor [43,44]. If you compare the
feasibility of chemotherapy in our collective with data in
literature, you can find a low cumulative dose for the
patients with CDAD [19].
In our collective only 19% of the patients received the
complete chemotherapy dose. For example of the
patients receiving Cisplatin only 3 of 13 patients
received at least 200 mg/m2 Cisplatin. The poor feasibil-
ity of chemotherapy in our collective might decrease the
loco regional control and overall survival for patients
suffering from a CDAD.
In summary with four patients dying due to CDAD, a
change from a curative to a palliative concept in another
four patients, CDAD is a severe problem for radioonco-
logical patients. Compared with the lethality of 0,5% to
2% described in literature the 11,8% in our collective
(four out of 34 patients) seems to be very high [3]. This
might be due to a negative selection of the patients. The
average age is high and patients had a high number of
risk factors, concomitant diseases and often a reduced
general condition.
There are several options reducing the risk of develop-
ing CDAD. Beside the restrictive use of antibiotics and
proton pump inhibitors, the upkeep of oral nutrition as
long as possible is essential in reducing the rate of
CDAD. Especially Moxifloxacin, which is known to trig-
ger CDAD, was not used since 2008 in clinical routine
[7,45]. The high rate of patients in our collective receiv-
ing Moxifloxacin until 2007 and the decreasing inci-
dence of CDAD since 2008 seemed to be an effect of
discontinuing Moxifloxacin in clinical use.
With these arrangements and an intensive screening
for Clostridium difficile the rate of infections has
declined from 16 cases in 2007 to 11 in 2008, 4 in 2009
and 2 in 2010.
Even though there is only little evidence in probiotics
reducing the rate of CDAD for patients at risk, we trea-
ted all patients with four or more risk factors frequently
[28,46-49].
Conclusion
The effect of CDAD on the feasibility of the radiother-
apy and a concomitant chemotherapy is remarkable.
The morbidity of patients is severe with a high lethality.
Reducing of risk factors, an intense screening and the
use of probiotics as prophylaxis can reduce the inci-
dence of CDAD.
List of abbreviations
CD: Clostridium difficile; CDAD: Clostridium difficile:associated diarrhea; KPS:
Karnofsky Performance Status; PPI: Proton pump inhibitor; SCCHN: Squamous
cell carcinoma of the head and neck
Authors’ contributions
MGH planned the design of the study, did identify the patients, register the
patients’ data, correlate the data and drafted the manuscript. MH was
participating in identification of patients data. OK participated in planning of
the study and its coordination. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 April 2011 Accepted: 1 August 2011
Published: 1 August 2011
References
1. Vaishnavi C: Clinical spectrum & pathogenesis of Clostridium difficile
associated diseases. Indian J Med Res 2010, 131:487-499.
2. Hookman P, Barkin JS: Clostridium difficile associated infection, diarrhea
and colitis. World J Gastroenterol 2009, 15:1554-1580.
3. Reichardt C, Chaberny IF, Kola A, Mattner F, Vonberg RP, Gastmeier P:
[Dramatic increase of Clostridium difficile-associated diarrhea in
Germany: has the new strain PCR-ribotype 027 already reached us?].
Dtsch Med Wochenschr 2007, 132:223-228.
4. Koh TH, Tan AL, Tan ML, Wang G, Song KP: Epidemiology of Clostridium
difficile infection in a large teaching hospital in Singapore. Pathology
2007, 39:438-442.
5. DuPont HL, Garey K, Caeiro J, Jiang Z: New advances in Clostridium
difficile infection: changing epidemiology, diagnosis, treatment and
control. Curr Opin Infect Dis 2008, 21:500-507.
6. Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML,
Drudy D, Fitzpatrick F, Wiuff C, Brown DJ, Coia JE, Pituch H, Reichert P,
Even J, Mossong J, Widmer AF, Olsen KE, Allerberger F, Notermans DW,
Delmée M, Coignard B, Wilcox M, Patel B, Frei R, Nagy E, Bouza E, Marin M,
Akerlund T, Virolainen-Julkunen A, Lyytikäinen O, Kotila S, Ingebretsen A,
Smyth B, Rooney P, Poxton IR, Monnet DL: Update of Clostridium difficile
infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008, 13.
7. Thomas C, Stevenson M, Riley TV: Antibiotics and hospital-acquired
Clostridium difficile-associated diarrhoea: a systematic review. J
Antimicrob Chemother 2003, 51:1339-1350.
8. Kaier K, Frank U: Relationship between antibiotic consumption and
Clostridium difficile-associated diarrhea: an epidemiological note.
Antimicrob Agents Chemother 2009, 53:4574-4575.
Hautmann et al. Radiation Oncology 2011, 6:89
http://www.ro-journal.com/content/6/1/89
Page 6 of 7
9. Kim JW, Lee KL, Jeong JB, Kim BG, Shin S, Kim JS, Jung HC, Song IS: Proton
pump inhibitors as a risk factor for recurrence of Clostridium-difficile-
associated diarrhea. World J Gastroenterol 2010, 16:3573-3577.
10. Aseeri M, Schroeder T, Kramer J, Zackula R: Gastric acid suppression by
proton pump inhibitors as a risk factor for clostridium difficile-associated
diarrhea in hospitalized patients. Am J Gastroenterol 2008, 103:2308-2313.
11. Vesta KS, Wells PG, Gentry CA, Stipek WJ: Specific risk factors for
Clostridium difficile-associated diarrhea: a prospective, multicenter, case
control evaluation. Am J Infect Control 2005, 33:469-472.
12. Gifford AH, Kirkland KB: Risk factors for Clostridium difficile-associated
diarrhea on an adult hematology-oncology ward. Eur J Clin Microbiol
Infect Dis 2006, 25:751-755.
13. Blot E, Escande M, Besson D, Barbut F, Granpeix C, Asselain B, Falcou MC,
Pouillart P: Outbreak of Clostridium difficile-related diarrhoea in an adult
oncology unit: risk factors and microbiological characteristics. J Hosp
Infect 2003, 53:187-192.
14. Hornbuckle K, Chak A, Lazarus HM, Cooper GS, Kutteh LA, Gucalp R,
Carlisle PS, Sparano J, Parker P, Salata RA: Determination and validation of
a predictive model for Clostridium difficile diarrhea in hospitalized
oncology patients. Ann Oncol 1998, 9:307-311.
15. Tai E, Richardson LC, Townsend J, Howard E, McDonald LC: Clostridium
difficile Infection Among Children With Cancer. Pediatr Infect Dis J 2011,
30:610-612.
16. Patyánik M, Nemeskéri C, Póti Z, Sinkó D, Pesznyák C, Király R, Kois R, Mayer A:
Concomitant radiochemotherapy of cervical cancer: is it justified to reduce
the dosage of cisplatin? Strahlenther Onkol 2009, 185:582-587.
17. Bernier J: Current state-of-the-art for concurrent chemoradiation. Semin
Radiat Oncol 2009, 19:3-10.
18. Wolff HA, Bosch J, Jung K, Overbeck T, Hennies S, Matthias C, Hess CF,
Roedel RM, Christiansen H: High-grade acute organ toxicity as positive
prognostic factor in primary radio(chemo)therapy for locally advanced,
inoperable head and neck cancer. Strahlenther Onkol 2010, 186:262-268.
19. Steinmann D, Cerny B, Karstens JH, Bremer M: Chemoradiotherapy with
weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a
cumulative dose-effect analysis. Strahlenther Onkol 2009, 185:682-688.
20. Manikantan K, Khode S, Sayed SI, Roe J, Nutting CM, Rhys-Evans P,
Harrington KJ, Kazi R: Dysphagia in head and neck cancer. Cancer Treat
Rev 2009, 35:724-732.
21. Wurstbauer K, Merz F, Sedlmayer F: Amphotericin B lozengers: prophylaxis
for esophagitis in thoracic radiotherapy: a prospective study. Strahlenther
Onkol 2009, 185:512-516.
22. Semrau S, Waldfahrer F, Lell M, Linke R, Klautke G, Kuwert T, Uder M, Iro H,
Fietkau R: Feasibility, Toxicity, and Efficacy of Short Induction
Chemotherapy of Docetaxel Plus Cisplatin or Carboplatin (TP) Followed
by Concurrent Chemoradio - therapy for Organ Preservation in
Advanced Cancer of the Hypopharynx, Larynx, and Base of Tongue. Early
Results. Strahlentherapie und Onkologie: Organ der Deutschen
Rontgengesellschaft ... [et al] 2010.
23. Anand A, Bashey B, Mir T, Glatt AE: Epidemiology, clinical manifestations,
and outcome of Clostridium difficile-associated diarrhea. Am J
Gastroenterol 1994, 89:519-523.
24. Crabtree T, Aitchison D, Meyers BF, Tymkew H, Smith JR, Guthrie TJ,
Munfakh N, Moon MR, Pasque MK, Lawton J, Moazami N, Damiano RJ Jr:
Clostridium difficile in cardiac surgery: risk factors and impact on
postoperative outcome. Ann Thorac Surg 2007, 83:1396-1402.
25. Yamazawa K, Kanno H, Seki K, Kuzuta T, Matsui H, Sekiya S: Life-threatening
Clostridium difficile-associated diarrhea induced by paclitaxel-carboplatin
combination chemotherapy. Acta Obstet Gynecol Scand 2001, 80:768-769.
26. Resnik E, Lefevre CA: Fulminant Clostridium difficile colitis associated with
paclitaxel and carboplatin chemotherapy. Int J Gynecol Cancer 1999, 9:512-514.
27. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW: Economic healthcare
costs of Clostridium difficile infection: a systematic review. J Hosp Infect
2010, 74:309-318.
28. Heinlen L, Ballard JD: Clostridium difficile infection. Am J Med Sci 2010,
340:247-252.
29. Fraunholz I, Rabeneck D, Weiss C, Rödel C: Combined-modality treatment
for anal cancer: current strategies and future directions. Strahlenther
Onkol 2010, 186:361-366.
30. Platteaux N, Dirix P, Vanstraelen B, Nuyts S: Outcome after Re-Irradiation of
Head and Neck Cancer Patients. Strahlentherapie und Onkologie: Organ der
Deutschen Rontgengesellschaft ... [et al] 2010.
31. Wolf M, Zehentmayr F, Niyazi M, Ganswindt U, Haimerl W, Schmidt M,
Hölzel D, Belka C: Long-term outcome of mitomycin C- and 5-FU-based
primary radiochemotherapy for esophageal cancer. Strahlenther Onkol
2010, 186:374-381.
32. Huguenin P, Glanzmann C, Taussky D, Lütolf UM, Schmid S, Moe K:
Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III
and -IV carcinomas of the head and neck. Long-term results including
functional outcome. Strahlenther Onkol 1998, 174:397-402.
33. Bliss DZ, Johnson S, Savik K, Clabots CR, Willard K, Gerding DN: Acquisition
of Clostridium difficile and Clostridium difficile-associated diarrhea in
hospitalized patients receiving tube feeding. Ann Intern Med 1998,
129:1012-1019.
34. O’Keefe SJD: Tube feeding, the microbiota, and Clostridium difficile
infection. World J Gastroenterol 2010, 16:139-142.
35. Beckmann GK, Hoppe F, Pfreundner L, Flentje MP: Hyperfractionated
accelerated radiotherapy in combination with weekly cisplatin for locally
advanced head and neck cancer. Head Neck 2005, 27:36-43.
36. Chopra T, Alangaden GJ, Chandrasekar P: Clostridium difficile infection in
cancer patients and hematopoietic stem cell transplant recipients. Expert
Rev Anti Infect Ther 2010, 8:1113-1119.
37. Leung S, Metzger BS, Currie BP: Incidence of Clostridium difficile infection
in patients with acute leukemia and lymphoma after allogeneic
hematopoietic stem cell transplantation. Infect Control Hosp Epidemiol
2010, 31:313-315.
38. Bese NS, Hendry J, Jeremic B: Effects of prolongation of overall treatment
time due to unplanned interruptions during radiotherapy of different
tumor sites and practical methods for compensation. Int J Radiat Oncol
Biol Phys 2007, 68:654-661.
39. van den Bogaert W, van der Leest A, Rijnders A, Delaere P, Thames H, van
der Schueren E: Does tumor control decrease by prolonging overall
treatment time or interrupting treatment in laryngeal cancer? Radiother
Oncol 1995, 36:177-182.
40. Maciejewski B, Preuss-Bayer G, Trott KR: The influence of the number of
fractions and of overall treatment time on local control and late
complication rate in squamous cell carcinoma of the larynx. Int J Radiat
Oncol Biol Phys 1983, 9:321-328.
41. Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, Byhardt RW,
Curran WJ: Effect of overall treatment time on outcomes after
concurrent chemoradiation for locally advanced non-small-cell lung
carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG)
experience. Int J Radiat Oncol Biol Phys 2005, 63:667-671.
42. Pignon J, Le Maître A, Maillard E, Bourhis J: Meta-analysis of
chemotherapy in head and neck cancer (MACH-NC): an update on
93 randomised trials and 17,346 patients. Radiother Oncol 2009,
92:4-14.
43. Foote: The Importance of Planned Dose of Chemotherapy on Time: Do
We Need to Change Our Clinical Practice? Oncologist 1998, 3:365-368.
44. Ho KF, Swindell R, Brammer CV: Dose intensity comparison between
weekly and 3-weekly Cisplatin delivered concurrently with radical
radiotherapy for head and neck cancer: a retrospective comparison from
New Cross Hospital, Wolverhampton, UK. Acta Oncol 2008, 47:1513-1518.
45. Pépin J, Saheb N, Coulombe M, Alary ME, Corriveau MP, Authier S,
Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L:
Emergence of fluoroquinolones as the predominant risk factor for
Clostridium difficile-associated diarrhea: a cohort study during an
epidemic in Quebec. Clin Infect Dis 2005, 41:1254-1260.
46. Miller K, Fraser T: Q: What is the role of probiotics in the treatment of
acute Clostridium difficile-associated diarrhea? Cleve Clin J Med 2009,
76:391-392.
47. Pillai A, Nelson R: Probiotics for treatment of Clostridium difficile-
associated colitis in adults. Cochrane Database Syst Rev 2008, CD004611.
48. Segarra-Newnham M: Probiotics for Clostridium difficile-associated
diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces
boulardii. Ann Pharmacother 2007, 41:1212-1221.
49. Monaghan T, Boswell T, Mahida YR: Recent advances in Clostridium
difficile-associated disease. Gut 2008, 57:850-860.
doi:10.1186/1748-717X-6-89
Cite this article as: Hautmann et al.: Clostridium difficile-associated
diarrhea in radiooncology: an underestimated problem for the
feasibility of the radiooncological treatment? Radiation Oncology 2011
6:89.
Hautmann et al. Radiation Oncology 2011, 6:89
http://www.ro-journal.com/content/6/1/89
Page 7 of 7
